Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMAB030A | — |
the patient received the orange topped lyophilized powder diluted with sterile water; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 18-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMAB030A) for prophylaxis. On 11-APR-2025, the patient received Menveo. On 11-APR-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: the patient received the orange topped lyophilized powder diluted with sterile water). The outcome of the wrong solution used in drug reconstitution was not applicable. Additional Information: GSK Receipt Date: 15-APR-2025 The pharmacist asked could tell if both vials of Menveo (2 vial kit) were not administered does the dose need to be repeated. The patient received the orange topped lyophilized powder diluted with sterile water, which led wrong solution used in drug reconstitution. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up.